Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gritstone bio Inc GRTSQ

Healthcare Biotechnology
Gritstone bio, Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates. It has developed two vectors that it deploys with the aim of eliciting the desired immune response: self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage... see more

Recent & Breaking News (PINL:GRTSQ)

The Omicron Variant of SARS-CoV-2 has Minimal Impact on the T Cell Epitopes (Targets) Contained within Gritstone's Self-Amplifying mRNA COVID-19 Vaccines

GlobeNewswire November 29, 2021

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 23, 2021

Gritstone Announces Positive Preclinical Data in Non-Human Primate Challenge Study with Second-Generation COVID-19 Vaccine Against SARS-CoV-2

GlobeNewswire November 10, 2021

Gritstone Reports Third Quarter 2021 Financial Results and Business Update

GlobeNewswire November 3, 2021

Gritstone Announces Presentations during Five Upcoming Investor Conferences and Events

GlobeNewswire October 25, 2021

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire September 24, 2021

Gritstone Announces Dosing of First Volunteer in Trial Evaluating Self-Amplifying mRNA as a COVID-19 Vaccine Booster and Immunogenicity Enhancer

GlobeNewswire September 20, 2021

Gritstone Announces Dosing of First Solid Tumor Patient with Optimized SLATE "Off-the-Shelf" Mutant KRAS-directed Neoantigen Immunotherapy in Phase 2 Clinical Trial

GlobeNewswire September 17, 2021

Gritstone Announces Positive Clinical Data with GRANITE (Individualized Neoantigen Immunotherapy Program) during ESMO 2021 and Launch of Randomized Clinical Trial Program in Colorectal Cancer with Registrational Intent

GlobeNewswire September 17, 2021

Gritstone Announces Private Placement Financing of $55.0 Million

GlobeNewswire September 16, 2021

Gritstone to Host Data Update on Neoantigen Oncology Programs for the Treatment of Solid Tumors During ESMO 2021

GlobeNewswire September 9, 2021

Gritstone Announces Presentations at Two Investor Conferences in September

GlobeNewswire September 7, 2021

Gritstone and CEPI Announce Agreement to Advance Second-Generation COVID-19 Vaccine Program (CORAL) Against SARS-CoV-2 Variants of Concern

GlobeNewswire August 17, 2021

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire August 16, 2021

Gritstone to Host Key Opinion Leader Webinar on its Neoantigen Oncology Programs

GlobeNewswire August 11, 2021

Gritstone Reports Second Quarter 2021 Financial Results and Business Update

GlobeNewswire August 5, 2021

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire July 15, 2021

Gritstone Announces Management Changes, Including the Appointment of Celia Economides as Chief Financial Officer

GlobeNewswire June 23, 2021

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire June 17, 2021

Gritstone to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

GlobeNewswire June 7, 2021